Calendar

The checked earnings source supplied EPS and revenue consensus, but no positive estimate revisions or verified pre-event accumulation/tape signal was found.

The checked source indicates the prior quarter missed EPS and revenue was pressured; the upcoming quarter is seasonally loss-making and no positive revision or tape setup was found.

The checked consensus source showed downward EPS and revenue revisions over three months, with no verified favorable tape or volume evidence.

Consensus and the prior-quarter beat are documented in checked sources, but no positive estimate revisions or required pre-event price/volume confirmation were found.

The checked search results conflict on the last reported period and upcoming date, and no credible event-specific consensus/revision or qualifying tape data was established.

Search results reported substantial goodwill/intangible impairments, a halved dividend, and below-consensus guidance; this presents a material balance-sheet and earnings-quality concern, while estimate and tape confirmation is weak.

A preview cited a revenue outlook increase and $9.7B consensus revenue, but current positive EPS revision and required tape/volume confirmations were not established.

FactSet's IR confirmed the release date and a current consensus source reports $4.38 EPS/$636.1M revenue, but no positive revisions or required tape evidence was verified.

Revenue estimate coverage exists and the retrieved daily snapshot shows a modest down day; no positive EPS revision or required accumulation pattern was established.

Positive ESP and a reported five-day gain support interest, but the retrieved tape did not show 1.5x-normal volume and sector-relative strength was not established; the setup misses required confirmation.

A Sep. 25 estimate sheet provides EPS/revenue consensus and next-period forecasts, but no verifiable positive revision, event-specific revenue upside, or required tape confirmation.

The checked preview indicates a near-term sales outlook below analyst expectations, and retrieved evidence did not establish the required favorable tape or revenue upside.

A secondary preview supplied EPS/revenue consensus and positive revision claims, but lacks dependable corroboration and required tape data; the earnings setup is not sufficiently evidenced.

Aehr has a reported 46.6% sequential revenue estimate increase and AI-related demand narrative, with a strong Sep. 25 session, but no positive EPS revision or qualifying 1.5x volume evidence was found.